Browse TTLL5

Summary
SymbolTTLL5
Nametubulin tyrosine ligase-like family member 5
Aliases KIAA0998; CORD19; STAMP; SRC1 and TIF2 associated binding protein; SRC1 and TIF2-associated modulatory prote ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell projection, cilium Cytoplasm, cytoskeleton, cilium basal body Nucleus Cytoplasm Note=Localized to the base of the connecting cilium between the basal body and the adjacent daughter centriole of the cilium. In osteosarcoma cells, found in both cytoplasm and nucleus in the absence of steroid but located exclusively in the nucleus in the presence of steroid.
Domain PF03133 Tubulin-tyrosine ligase family
Function

Polyglutamylase which preferentially modifies alpha-tubulin. Involved in the side-chain initiation step of the polyglutamylation reaction rather than in the elongation step (By similarity). Required for CCSAP localization to both spindle and cilia microtubules. Increases the effects of NCOA2 in glucocorticoid receptor-mediated repression and induction and in androgen receptor-mediated induction (PubMed:17116691, PubMed:22493317).

> Gene Ontology
 
Biological Process GO:0000226 microtubule cytoskeleton organization
GO:0001578 microtubule bundle formation
GO:0001654 eye development
GO:0007281 germ cell development
GO:0007283 spermatogenesis
GO:0007286 spermatid development
GO:0007288 sperm axoneme assembly
GO:0007423 sensory organ development
GO:0009566 fertilization
GO:0010927 cellular component assembly involved in morphogenesis
GO:0018095 protein polyglutamylation
GO:0018200 peptidyl-glutamic acid modification
GO:0022412 cellular process involved in reproduction in multicellular organism
GO:0030031 cell projection assembly
GO:0030317 flagellated sperm motility
GO:0035082 axoneme assembly
GO:0042384 cilium assembly
GO:0043010 camera-type eye development
GO:0044782 cilium organization
GO:0048232 male gamete generation
GO:0048515 spermatid differentiation
GO:0060041 retina development in camera-type eye
GO:0060271 cilium morphogenesis
GO:0097722 sperm motility
Molecular Function GO:0016874 ligase activity
Cellular Component GO:0005813 centrosome
GO:0005874 microtubule
GO:0005929 cilium
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolTTLL5
Nametubulin tyrosine ligase-like family member 5
Aliases KIAA0998; CORD19; STAMP; SRC1 and TIF2 associated binding protein; SRC1 and TIF2-associated modulatory prote ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TTLL5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTTLL5
Nametubulin tyrosine ligase-like family member 5
Aliases KIAA0998; CORD19; STAMP; SRC1 and TIF2 associated binding protein; SRC1 and TIF2-associated modulatory prote ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TTLL5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -1.47; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolTTLL5
Nametubulin tyrosine ligase-like family member 5
Aliases KIAA0998; CORD19; STAMP; SRC1 and TIF2 associated binding protein; SRC1 and TIF2-associated modulatory prote ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TTLL5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3420.222
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.8670.483
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0350.967
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1110.676
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1750.943
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.4720.879
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0020.995
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1310.922
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.130.93
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1870.874
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7680.637
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0780.178
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TTLL5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.2022.20.12
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47500500.109
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTTLL5
Nametubulin tyrosine ligase-like family member 5
Aliases KIAA0998; CORD19; STAMP; SRC1 and TIF2 associated binding protein; SRC1 and TIF2-associated modulatory prote ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TTLL5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTTLL5
Nametubulin tyrosine ligase-like family member 5
Aliases KIAA0998; CORD19; STAMP; SRC1 and TIF2 associated binding protein; SRC1 and TIF2-associated modulatory prote ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TTLL5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TTLL5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTTLL5
Nametubulin tyrosine ligase-like family member 5
Aliases KIAA0998; CORD19; STAMP; SRC1 and TIF2 associated binding protein; SRC1 and TIF2-associated modulatory prote ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TTLL5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTTLL5
Nametubulin tyrosine ligase-like family member 5
Aliases KIAA0998; CORD19; STAMP; SRC1 and TIF2 associated binding protein; SRC1 and TIF2-associated modulatory prote ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TTLL5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTTLL5
Nametubulin tyrosine ligase-like family member 5
Aliases KIAA0998; CORD19; STAMP; SRC1 and TIF2 associated binding protein; SRC1 and TIF2-associated modulatory prote ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TTLL5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTTLL5
Nametubulin tyrosine ligase-like family member 5
Aliases KIAA0998; CORD19; STAMP; SRC1 and TIF2 associated binding protein; SRC1 and TIF2-associated modulatory prote ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TTLL5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.